Neurocutaneous Disorder Market Research Report Information By Type (Tuberous Sclerosis (TS), Neurofibromatosis (NF), Sturge-Weber Syndrome, A-T, VHL), by Diagnosis (MRI, CT, EEG), End-User (Hospitals & Clinics, Diagnostic Centers) – Forecast Till 2030

Neurocutaneous Disorder Market Scenario

Neurocutaneous disorder market is expected to USD 28.14 billion at a CAGR of approximately 20.10% during the forecast period 2023 - 2030. The neurocutaneous syndrome is a group of neurologic disorders of brain, spine, and the peripheral nervous system. These diseases are lifelong conditions that may induce a tumor growth inside the skin, organs, skeletal bones, brain, and spinal cord.

These disorders are usually genetic and arise due to abnormal cell development at the embryo stage. The result is characterized by the development of tumors in various parts of the body. Even though some can be diagnosed at birth, most of them do not display symptoms until late. These syndromes cannot be cured, but various treatments can assist to manage the symptoms and any health concern. Lately, significant advances have been made by the use of DNA testing to confirm these syndromes in some people.

The three most common types of neurocutaneous syndromes are Tuberous sclerosis (TS), Neurofibromatosis (NF): Type I, Type II, and schwannomatosis, and Sturge-Weber disease.

Tuberous sclerosis (TS) is a non-cancerous growth that occurs in organs such as brain, eyes, kidneys, heart, lungs, bones, and skin. There is a 50% chance of children to develop TS if the parent is affected by it. Moreover, the Sturge-Weber Syndrome (SWS) causes malformations relating to the face, eye, and brain. It is estimated that about 1 in 20,000 to 50,000 live births may be affected with the Sturge-Weber syndrome.

Increasing government initiatives for ensuring the early diagnosis is supposed to be a significant driver of the neurocutaneous disorder market. Moreover, many guidelines are issued by government organizations to promote awareness related to effective prevention measures, globally. All these factors are expected to contribute to the market growth throughout the forecast period. Moreover, concerns regarding the safety of reprocessed instruments and stringent regulations for sterilization equipment manufacturers and service providers are factors hampering the neurocutaneous disorder market growth.

Intended Audience

• Clinical and diagnostic labs


• Pharmaceutical and biotechnology companies


• Regulatory bodies


• Medical device companies


• Healthcare providers


• Research and consulting firms


• Venture capitalists and investors

Figure 1: Neurocutaneous Disorder Market Share, by Region

Segmentation

The neurocutaneous disorder market has been segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the neurocutaneous disorder market can be segmented into Tuberous Sclerosis (TS), Neurofibromatosis (NF), Sturge-weber syndrome, Ataxia-Telangiectasia (A-T), Von Hippel-Lindau disease (VHL), and others.

Neurofibromatosis (NF) is further divided into Neurofibromatosis type 1 (NF1), Neurofibromatosis type 2 (NF2), and schwannomatosis. The Sturge-weber syndrome is divided into type-1, type-2, and type-3.

On the basis of diagnosis, the neurocutaneous disorder market can be segmented into skull radiography, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, Electroencephalogram (EEG), genetic tests (blood testing), biopsy, and others

On the basis of treatment, the global neurocutaneous disorder market can be segmented into medication, laser therapy, surgical procedures, and others.

Medication is further divided into antiepileptic, beta-antagonist eye drops, carbonic anhydrase inhibitors, adrenergic eye drops, miotic eye drops, and others. Surgical procedures are further divided into focal cortical resection, hemispherectomy, corpus callosotomy, trabeculectomy, filtration surgery, cyclocryotherapy, Vagal Nerve Stimulation (VNS), and others.

On the basis of end-user, the neurocutaneous disorder market is segmented into hospitals and clinics, diagnostic centers, and others.

Regional Analysis

The neurocutaneous disorder market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas region accounted for the largest market share of the neurocutaneous disorder market owing to the increasing awareness about genetic disorders along with the growing number of drug and medical service providers. As per the National Institute of Neurological Disorders and Stroke (NINDS) in 2017, Neurofibromatosis Type 1 (NF1) occurs in about 1 in 3,000 to 4,000 births in the U.S. This condition is a chromosomal disorder which is inherited from a parent. Moreover, Neurofibromatosis Type 2 (NF2) occurs less frequently, affecting about 1 in 25,000 births in the U.S.

The European neurocutaneous disorder market is the second largest market followed by Asia Pacific. The Asia Pacific region is expected to exhibit the fastest growth throughout the forecast period owing to the exceptional healthcare standards and infrastructure, rising healthcare expenditure, and growing presence of outsourcing organizations across this region. Moreover, the presence of various government organizations dedicated to improving the standards for neurocutaneous disorders is among the significant factors contributing towards the growth of the Asia Pacific region.

The Middle Eastern region is expected to grow at a steady pace owing to factors such as the extensive development of the healthcare infrastructure and increasing R&D activities in the healthcare sector.

Key Players

Some of the key players in the neurocutaneous disorder market are Valeant Pharmaceuticals International, Inc. (U.S.), Allergan (U.S.), Syneron Medical Ltd (U.S.), Medtronic Plc (U.S.), Cutera, Inc. (U.S.), St Jude Medical, Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Abbott Laboratories Inc. (U.S.), UCB S.A. (Belgium), Sanofi SA (France), Shire Plc (Ireland),  F. Hoffmann-La Roche AG (Switzerland), Aleva Neurotherapeutics SA (Switzerland), Johnson & Johnson (U.S.), and others.